In addition, a recently published study assessed the impact of clazakizumab, an anti-IL-6 antibody, in kidney transplant recipients with antibody-mediated rejection (ABMR) on CYP3A and CYP2C19 activity by pantoprazole and on tacrolimus and CyA concentrations (Mühlbacher et al., 2021). The gene discussed is CYP2C19; the disease is kidney transplant.